Takanori Matsuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takanori Matsuki has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Kazuyuki Tsujino
Department of Respiratory Medicine, National Hospital Organization, Osaka Toneyama Medical Center , Osaka
5 shared publicationsTakuro Nii
Department of Respiratory Medicine, National Hospital Organization, Osaka Toneyama Medical Center , Osaka
5 shared publications- Keisuke Miki
Department of Respiratory Medicine, National Hospital Organization, Osaka Toneyama Medical Center , Osaka
4 shared publications - Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Suita, Japan
3 shared publications Hiroshi Kida
Department of Respiratory Medicine, National Hospital Organization, Osaka Toneyama Medical Center , Osaka
3 shared publications- Hiroshi Kida
Department of Respiratory Medicine, National Hospital Organization, Osaka Toneyama Medical Centre, Toyonaka, Japan
2 shared publications
Latest Publications
- 24 April 2026
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 38 (8) , 521-534
Distinct fibrosis-associated macrophage subsets coordinate iron metabolism in pulmonary fibrosis
Pulmonary fibrosis has a poor prognosis due to challenges in early diagnosis and therapeutic intervention. Current treatments remain largely ineffective due to an incomplete understanding of the complex pathology, including the interactions between fibroblasts and profibrotic immune cells within fibrotic lungs. To elucidate the dynamics of fibrosis, we performed single-cell RNA sequencing (scRNA-seq) on bronchoalveolar lavage fluid (BALF) obtained from patients with interstitial lung disease (ILD). We identified the SPP1- and APOE-expressing macrophage population that is commonly present across ILDs. Histological analysis showed that this macrophage population accumulated at the center of fibrotic foci. Furthermore, the ratio of this macrophage population was increased in both progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF). Transcriptomic analysis further divided this macrophage population into two subsets: SLC40A1+ or HAMP+ fibrosis-associated macrophages. We found that the relative balance of IL-10 and IL-8 regulated SLC40A1 and HAMP expression within fibrosis-associated macrophages. Additionally, histological analysis revealed that bronchial epithelium expressed IL-8, while type II alveolar epithelial cells expressed IL-10 in the fibrotic lung. SLC40A1+ fibrosis-associated macrophages localized to CD31+ perivascular regions and mediated the uptake and degradation of the hemoglobin–haptoglobin complex. This dual pathway—providing iron via SLC40A1 and intracellular iron accumulation via HAMP—facilitated the transition of fibroblasts into SPP1+ myofibroblasts. Moreover, ferroptotic fibroblasts secreted TGF-β1, which further contributes to fibrotic progression. In conclusion, aberrant iron metabolism orchestrated by fibrosis-associated macrophages may contribute to fibrosis by facilitating the transition of myofibroblasts. These findings provide mechanistic insight into the progression of autonomous pulmonary fibrosis.
- 24 April 2026
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 38 (8) , 521-534
Distinct fibrosis-associated macrophage subsets coordinate iron metabolism in pulmonary fibrosis
Pulmonary fibrosis has a poor prognosis due to challenges in early diagnosis and therapeutic intervention. Current treatments remain largely ineffective due to an incomplete understanding of the complex pathology, including the interactions between fibroblasts and profibrotic immune cells within fibrotic lungs. To elucidate the dynamics of fibrosis, we performed single-cell RNA sequencing (scRNA-seq) on bronchoalveolar lavage fluid (BALF) obtained from patients with interstitial lung disease (ILD). We identified the SPP1- and APOE-expressing macrophage population that is commonly present across ILDs. Histological analysis showed that this macrophage population accumulated at the center of fibrotic foci. Furthermore, the ratio of this macrophage population was increased in both progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF). Transcriptomic analysis further divided this macrophage population into two subsets: SLC40A1+ or HAMP+ fibrosis-associated macrophages. We found that the relative balance of IL-10 and IL-8 regulated SLC40A1 and HAMP expression within fibrosis-associated macrophages. Additionally, histological analysis revealed that bronchial epithelium expressed IL-8, while type II alveolar epithelial cells expressed IL-10 in the fibrotic lung. SLC40A1+ fibrosis-associated macrophages localized to CD31+ perivascular regions and mediated the uptake and degradation of the hemoglobin–haptoglobin complex. This dual pathway—providing iron via SLC40A1 and intracellular iron accumulation via HAMP—facilitated the transition of fibroblasts into SPP1+ myofibroblasts. Moreover, ferroptotic fibroblasts secreted TGF-β1, which further contributes to fibrotic progression. In conclusion, aberrant iron metabolism orchestrated by fibrosis-associated macrophages may contribute to fibrosis by facilitating the transition of myofibroblasts. These findings provide mechanistic insight into the progression of autonomous pulmonary fibrosis.
- Open Access
- 27 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Gastric Aspirate Isolate Demonstrates Strain-Level Concordance With Sputum Isolate in Nontuberculous Mycobacterial Pulmonary Disease
The nontuberculous mycobacteria (NTM) isolated from gastric aspirate have demonstrated >85% strain concordance with those from the sputum, suggesting that they originate from the lungs rather than the environment. Gastric aspirate, although not yet internationally recognized, may be a useful supplementary specimen for diagnosing NTM pulmonary disease.
- 27 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Open AccessGastric Aspirate Isolate Demonstrates Strain-Level Concordance With Sputum Isolate in Nontuberculous Mycobacterial Pulmonary Disease
The nontuberculous mycobacteria (NTM) isolated from gastric aspirate have demonstrated >85% strain concordance with those from the sputum, suggesting that they originate from the lungs rather than the environment. Gastric aspirate, although not yet internationally recognized, may be a useful supplementary specimen for diagnosing NTM pulmonary disease.
- Open Access
- 10 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70318
Risk Factors for Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis: The Protective Potential of Salazosulfapyridine
Objectives: The aim of this study was to identify the risk factors for Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA) and to recommend appropriate disease‐modifying antirheumatic drug (DMARD) selection for those at high risk of developing PCP. Methods: We conducted a retrospective review of patients with RA who were treated with methotrexate or biologic and targeted synthetic DMARDs (b/tsDMARDs). Patients with no chest computed tomography data or those receiving prophylactic sulfamethoxazole–trimethoprim, atovaquone, or inhaled pentamidine were excluded. Results: Among 554 patients who met the inclusion and exclusion criteria, 16 developed PCP. Multivariate logistic analysis revealed interstitial pneumonia as a significant risk factor for PCP (odds ratio: 4.53, 95% confidence interval: 1.51–13.12), whereas salazosulfapyridine (SASP) use was associated with a reduced risk (odds ratio: 0.11, 95% confidence interval: 0.00–0.81). A Kaplan–Meier analysis comparing the cumulative incidence of PCP between propensity score‐matched SASP users and nonusers further demonstrated that SASP use reduced the risk of developing PCP. Conclusion: Patients with RA complicated by interstitial pneumonia are at a higher risk of developing PCP. Although methotrexate and b/tsDMARDs do not increase the risk of developing PCP, SASP may potentially reduce the risk. A prospective study is warranted to investigate the efficacy and safety of SASP in patients with RA at high risk for PCP.
- 10 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70318
Open AccessRisk Factors for Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis: The Protective Potential of Salazosulfapyridine
Objectives: The aim of this study was to identify the risk factors for Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA) and to recommend appropriate disease‐modifying antirheumatic drug (DMARD) selection for those at high risk of developing PCP. Methods: We conducted a retrospective review of patients with RA who were treated with methotrexate or biologic and targeted synthetic DMARDs (b/tsDMARDs). Patients with no chest computed tomography data or those receiving prophylactic sulfamethoxazole–trimethoprim, atovaquone, or inhaled pentamidine were excluded. Results: Among 554 patients who met the inclusion and exclusion criteria, 16 developed PCP. Multivariate logistic analysis revealed interstitial pneumonia as a significant risk factor for PCP (odds ratio: 4.53, 95% confidence interval: 1.51–13.12), whereas salazosulfapyridine (SASP) use was associated with a reduced risk (odds ratio: 0.11, 95% confidence interval: 0.00–0.81). A Kaplan–Meier analysis comparing the cumulative incidence of PCP between propensity score‐matched SASP users and nonusers further demonstrated that SASP use reduced the risk of developing PCP. Conclusion: Patients with RA complicated by interstitial pneumonia are at a higher risk of developing PCP. Although methotrexate and b/tsDMARDs do not increase the risk of developing PCP, SASP may potentially reduce the risk. A prospective study is warranted to investigate the efficacy and safety of SASP in patients with RA at high risk for PCP.
- Open Access
- 29 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1155
NHERF2 as a Novel Biomarker for Distinguishing MAC Pulmonary Disease from Tuberculosis Based on Proteome Analysis of Serum Extracellular Vesicles
Nontuberculous mycobacterial pulmonary disease (NTM-PD), mainly caused by Mycobacterium avium complex (MAC), and pulmonary tuberculosis (TB) are emerging health problems worldwide. However, because their clinical features are often similar, it remains difficult to differentiate NTM-PD from TB when the diagnosis cannot be made by sputum culture. To investigate potential serum biomarkers, we conducted non-targeted proteome analysis on serum extracellular vesicles (EVs) collected from 10 patients with MAC pulmonary disease (MAC-PD), 7 patients with TB, and 10 healthy controls. A total of 2614 proteins were identified in the discovery cohort. The EV protein signature from patients with NTM-PD and TB reflected infectious diseases and inflammatory response pathways. Among the identified proteins, the expression of Na+/H+ exchanger regulatory factor 2 (NHERF2) was significantly elevated in patients with MAC-PD compared with healthy controls and patients with TB. Moreover, upregulation of NHERF2 was confirmed by immunoblotting of serum EVs and immunohistochemistry of lungs with mycobacterial infection. Our findings highlight that NHERF2 in serum EVs might be a potential biomarker for distinguishing MAC-PD from TB, possibly reflecting the pathogenesis of MAC-PD.
- 29 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1155
Open AccessNHERF2 as a Novel Biomarker for Distinguishing MAC Pulmonary Disease from Tuberculosis Based on Proteome Analysis of Serum Extracellular Vesicles
Nontuberculous mycobacterial pulmonary disease (NTM-PD), mainly caused by Mycobacterium avium complex (MAC), and pulmonary tuberculosis (TB) are emerging health problems worldwide. However, because their clinical features are often similar, it remains difficult to differentiate NTM-PD from TB when the diagnosis cannot be made by sputum culture. To investigate potential serum biomarkers, we conducted non-targeted proteome analysis on serum extracellular vesicles (EVs) collected from 10 patients with MAC pulmonary disease (MAC-PD), 7 patients with TB, and 10 healthy controls. A total of 2614 proteins were identified in the discovery cohort. The EV protein signature from patients with NTM-PD and TB reflected infectious diseases and inflammatory response pathways. Among the identified proteins, the expression of Na+/H+ exchanger regulatory factor 2 (NHERF2) was significantly elevated in patients with MAC-PD compared with healthy controls and patients with TB. Moreover, upregulation of NHERF2 was confirmed by immunoblotting of serum EVs and immunohistochemistry of lungs with mycobacterial infection. Our findings highlight that NHERF2 in serum EVs might be a potential biomarker for distinguishing MAC-PD from TB, possibly reflecting the pathogenesis of MAC-PD.
- 20 September 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 1058-1063
Exercise intolerance and oxygen dynamics in nontuberculous mycobacteria with bronchiectasis
- 20 September 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 1058-1063
Exercise intolerance and oxygen dynamics in nontuberculous mycobacteria with bronchiectasis
- 18 January 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (2) , 258-261
Body positioning-related laryngeal narrowing pattern and expiratory mechanical constraints in advanced chronic obstructive pulmonary disease: A case report
- 18 January 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (2) , 258-261
Body positioning-related laryngeal narrowing pattern and expiratory mechanical constraints in advanced chronic obstructive pulmonary disease: A case report